Author

Kendra Worthington

University of Colorado Boulder

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:rat· 1

Frequent Co-Authors

Amy R. Perry· 1 shared Chima V. MadukaiD· 1 shared Francis G. SpinaleiD· 1 shared Gabriel J. Rodriguez‐RiveraiD· 1 shared Jason A. BurdickiD· 1 shared Mackenzie C. ObenrederiD· 1 shared Manuela Garay‐SarmientoiD· 1 shared Sara Boyd· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

9 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBioengineering

Amy R. Perry

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Engineering nanoparticles that target fibroblast activation protein in cardiac fibrosis

Chima V. Maduka, Gabriel J. Rodriguez‐Rivera, Manuela Garay‐Sarmiento, Amy R. Perry, Sara Boyd, Kendra Worthington, Mackenzie C. Obenreder, Stella Rydahl-Kim, Francis G. Spinale, Jason A. Burdick

This paper develops anti-FAP antibody-modified nanoparticles that target cardiac fibrosis in a rat model, reducing talabostat dose by 400,000-fold and reversing fibrosis and dysfunction.

bioRxiv · Apr 23, 2025 · PreprintBioengineering